# US 2019/0169694 A1 · Methods and materials for staging and treating skin cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169694 A1
- Document ID: US20190169694A1
- Status: Published application
- Kind: A1
- Application number: 16/099,483
- Filed: 2017-05-10
- Published: 2019-06-06
- Earliest claimed: 2016-05-10
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Alexander Meves
- Web page: https://patentgrep.com/patent/US20190169694A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 35/00: Antineoplastic agents
- G01N 33/5751: of the skin, e.g. melanoma
- G16B 25/00: ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B 25/10: Gene or protein expression profiling; Expression-ratio estimation or normalisation
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

This document provides methods and materials for staging and treating skin cancer (e.g., metastatic malignant pigmented skin lesions). For example, methods and materials for using an ITLP expression profile and/or models including an ITLP expression profile to stage skin cancer and/or determine treatment options for skin cancer patients are provided.

## Claims

### Claim 1

A method for treating a mammal having skin cancer, wherein said method comprises:
(a) determining a tumor-node-metastasis (TNM) stage of said skin cancer using a TNM staging system,
(b) determining that said skin cancer is ITLP positive, and
(c) treating said mammal using a cancer treatment for a stage one greater than said TNM stage.

### Claim 2 (depends on 1)

The method of claim 1, wherein said mammal is a human.

### Claim 3 (depends on 1)

The method of claim 1, wherein said skin cancer is pre-metastatic skin cancer.

### Claim 4 (depends on 1)

The method of claim 1, wherein said skin cancer is pre-metastatic melanoma.

### Claim 5

A method for assessing skin cancer, wherein said method comprises:
(a) determining the expression levels of ITGB3, TP53, LAMB1, and PLAT in skin cancer cells obtained from a mammal having skin cancer, and
(b) classifying said skin cancer as being ITLP negative or ITLP positive based on said expression levels.

### Claim 6 (depends on 5)

The method of claim 5, wherein said skin cancer is classified as being ITLP negative if said skin cancer is determined to have (i) an RNA copy number for ITGB that is less than or equal to 10, (ii) an RNA copy number for TP53 that is greater than 50, and (iii) neither an RNA copy number for LAMB1 that is greater than 250 nor an RNA copy number for PLAT that is greater than 427.

### Claim 7 (depends on 5)

The method of claim 5, wherein said skin cancer is classified as being ITLP positive if said skin cancer is determined not to have an RNA copy number for ITGB that is less than or equal to 10.

### Claim 8 (depends on 5)

The method of claim 5, wherein said skin cancer is classified as being ITLP positive if said skin cancer is determined not to have an RNA copy number for TP53 that is greater than 50.

### Claim 9 (depends on 5)

The method of claim 5, wherein said skin cancer is classified as being ITLP positive if said skin cancer is determined to have an RNA copy number for LAMB1 that is greater than 250.

### Claim 10 (depends on 5)

The method of claim 5, wherein said skin cancer is classified as being ITLP positive if said skin cancer is determined to have an RNA copy number for PLAT that is greater than 427.